Lipid profile changes by high activity anti-retroviral therapy

• Type: Article in International Scientific Journal
• Date: 2013

Authors

Duro, M (Author) Other; Sarmento Castro, R (Author) Other; Almeida, C (Author) Other; Medeiros, R (Author) ICBAS; Rebelo, I (Author) FFUP

Journal

Title: Clinical Biochemistry

Vol. 46

Pages: 740-744

ISSN: 0009-9120

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 13 Citations

Scopus - 15 Citations

Scientific classification

FOS: Engineering and technology > Medical engineering

Other information

Authenticus ID: P-005-084

DOI: 10.1016/j.clinbiochem.2012.12.017

Abstract (EN): Objective: Study of the lipid profile in patients infected with HIV treated with different combinations of high activity anti-retroviral therapy (HAART). Design and methods: A retrospective cohort study of the lipid profile in patients undergoing HAART. The study analyzes the evolution of concentrations of triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDLc) and HDL-cholesterol (HDLc) in a period of at least 3 years of treatment. From a total of 750 clinical cases analyzed in Hospital Joaquim Urbano (Oporto, Portugal) 124 patients were selected for this study. Results: After 3 years of treatment, we observed the development of dyslipidaemia by increases in TG (17%), TC (29%) and LDLc (9%), particularly in patients treated with a combination of drugs which included protease inhibitors (PI). Moreover, the non-nucleoside reverse transcriptase inhibitors (NNRTI) were associated with better lipid profile. The increase of 46% in HDLc was the most surprising finding. Conclusions: The results indicate that patients with HAART have a more atherogenic lipidic profile with increased TC, LDLc and TG levels. Since the effectiveness of NNRTI is similar to that of PI, but with a smaller atherogenic profile, it should be the first choice drug to be selected in the HIV treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5